Abstract
The biocompatibility of cardiovascular devices has always been considered crucial for their clinical efficacy. Therefore, a biofunctional coating composed of Type IV collagen (CoIV) and hyaluronan (HA) was previously fabricated onto the titanium (Ti) substrate for the application of promoting vascular smooth muscle cell contractile phenotype and improving surface endothelialization. However, the anti-inflammation property, blood compatibility and in vivo tissue compatibility of the HA/CoIV coating, as paramount consideration of cardiovascular materials surface coating, have not been investigated. Thus, in this study, the three crucial properties of the HA/CoIV coating were tested. The platelet adhesion/activation test and the dynamic whole blood experiment implied that the HA/CoIV coating had better blood compatibility compared with Ti substrate and pure CoIV coating. The macrophage adhesion/activation and inflammatory cytokine release (tumor necrosis factor-alpha and interleukin-1) results indicated that the HA/CoIV coating could significantly improve the anti-inflammation property of the Ti substrate. The in vivo implantation of SD rats for 3 weeks’ results demonstrated that the HA/CoIV coating caused milder tissue response. All these results suggested that the multi-functional HA/CoIV coating possessed good biocompatibility. This research is anticipated to be potentially applied for the surface modification of cardiovascular stents.
Highlights
Cardiovascular implant applied on the clinical treatment of cardiovascular disease (CVD) should perform its function with good blood compatibility, especially in the early stages after implantation [1]
It was clear that the platelets on the CoIV/TiOH possessed the biggest activated ratio, while it was interesting that the more CoIV on the HA/CoIV coating didn’t make more activation
From the statistical count results of macrophages on each sample in Fig. 5B, the HA/ CoIV coating and HA/TiOH sample exhibited significantly less adherent macrophages compared with Ti, TiOH and CoIV/TiOH samples. These results indicated that the HA/CoIV coating could inhibit macrophage adhesion and activation effectively
Summary
Cardiovascular implant applied on the clinical treatment of cardiovascular disease (CVD) should perform its function with good blood compatibility, especially in the early stages after implantation [1]. The effects of this multi-functional HA/CoIV coating on anti-coagulation and inhibition of inflammation have not been evaluated, and its in vivo tissue compatibility has not been investigated. The blood compatibility (platelet adhesion/ activation and the whole blood performance) and anti-inflammation property (macrophage adhesion/activation and inflammatory cytokines release) on the HA/CoIV coating were investigated, respectively (Fig. 1).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
